Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C15H14N4O.H2O |
Molecular Weight | 550.611 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC=NC2=C1NC(=O)C3=C(N=CC=C3)N2C4CC4.CC5=CC=NC6=C5NC(=O)C7=C(N=CC=C7)N6C8CC8
InChI
InChIKey=KMTLSXAXTLQBKJ-UHFFFAOYSA-N
InChI=1S/2C15H14N4O.H2O/c2*1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10;/h2*2-3,6-8,10H,4-5H2,1H3,(H,18,20);1H2
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C15H14N4O |
Molecular Weight | 266.2979 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00238Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Sources: http://www.drugbank.ca/drugs/DB00238
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. Nevirapine is used for use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22514580
Curator's Comment: Nevirapine (NVP) crosses well the BBB
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL614530 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26086472 |
239.0 µM [EC50] | ||
Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25240095 |
0.31 nM [EC50] | ||
Target ID: CHEMBL247 Sources: http://www.drugbank.ca/drugs/DB00238 |
250.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Viramune Approved UseVIRAMUNE is an NNRTI indicated for combination antiretroviral treatment of HIV-1 infection Launch Date1995 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2060 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82000 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
96700 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
161000 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40% |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Overdose |
unhealthy, 8-days-old n = 1 Health Status: unhealthy Age Group: 8-days-old Sex: F Population Size: 1 Sources: |
Other AEs: Neutropenia, Hyperlactatemia... |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Disc. AE: Rash, Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Page: p. 56Stevens-Johnson syndrome (1%) Transaminases increased (1%) ALT increased (1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (1%) Malaise (1%) Pyrexia (1%) Fatigue (1%) Vascular disorders (<1%) |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Disc. AE: Rash, Drug rash with eosinophilia and systemic symptoms... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Page: p. 56Drug rash with eosinophilia and systemic symptoms (<1%) Transaminases increased (1%) ALT increased (<1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (<1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (<1%) Malaise (<1%) Pyrexia (<1%) Fatigue (<1%) Vascular disorders (<1%) Musculoskeletal and connective tissue disorders (<1%) |
800 mg 1 times / day multiple, oral Overdose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Hepatotoxicity, Reaction skin... AEs leading to discontinuation/dose reduction: Hepatotoxicity (grade 5) Sources: Reaction skin (severe) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperlactatemia | 200 mg single, oral Overdose |
unhealthy, 8-days-old n = 1 Health Status: unhealthy Age Group: 8-days-old Sex: F Population Size: 1 Sources: |
|
Neutropenia | mild | 200 mg single, oral Overdose |
unhealthy, 8-days-old n = 1 Health Status: unhealthy Age Group: 8-days-old Sex: F Population Size: 1 Sources: |
ALT increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Fatigue | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatotoxicity | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Malaise | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Nausea | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Pyrexia | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Stevens-Johnson syndrome | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Transaminases increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Rash | 2% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
AST increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
GGT increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatic enzyme increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis acute | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis toxic | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Vascular disorders | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Transaminases increased | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Rash | 2% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
ALT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
AST increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Drug rash with eosinophilia and systemic symptoms | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Fatigue | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
GGT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatic enzyme increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatitis acute | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatitis toxic | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatotoxicity | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Malaise | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Musculoskeletal and connective tissue disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Nausea | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Pyrexia | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Vascular disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatotoxicity | grade 5 Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Reaction skin | severe Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Severe hepatic failure related to nevirapine treatment. | 1999 Aug |
|
Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. | 1999 Aug 20 |
|
Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. | 1999 Mar |
|
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group. | 1999 Oct 1 |
|
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. | 2000 Apr 10 |
|
Didanosine-induced hepatitis. | 2000 Aug |
|
Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine. | 2000 Feb 15 |
|
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. | 2000 Jul |
|
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. | 2000 Sep 18 |
|
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. | 2001 |
|
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. | 2001 Apr |
|
Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome. | 2001 Apr 1 |
|
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. | 2001 Apr 15 |
|
[Highly active antiretroviral therapy with nevirapine. Therapy compliance determines success]. | 2001 Apr 2 |
|
Antiviral drugs: current state of the art. | 2001 Aug |
|
Galactorrhoea, hyperprolactinaemia, and protease inhibitors. | 2001 Feb 10 |
|
Drug interaction between St John's wort and nevirapine. | 2001 Feb 16 |
|
Pharmacokinetic of nevirapine in haemodialysis. | 2001 Jan |
|
Ritonavir-induced carbamazepine toxicity. | 2001 Jan |
|
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. | 2001 Jan 5 |
|
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. | 2001 Jul 1 |
|
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. | 2001 Jun |
|
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. | 2001 Jun 1 |
|
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. | 2001 Mar 1 |
|
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. | 2001 Mar 1 |
|
Sequencing antiretroviral drugs. | 2001 Mar 30 |
|
Jaundice and hepatocellular damage associated with nevirapine therapy. | 2001 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/nevirapine.html
The recommended dose for Nevirapine is one 200 mg tablet daily for the first 14 days, followed by one 200 mg tablet twice daily, in combination with other antiretroviral agents.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16752922
The IC50 value for inhibition by nevirapine against immunodeficiency virus type 1 (HIV) nucleoside reverse transcriptase (RT) in removal assay was 3 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 21:18:13 GMT 2023
by
admin
on
Fri Dec 15 21:18:13 GMT 2023
|
Record UNII |
B7XF2TD73C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1460714
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
DBSALT002723
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
100000127941
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
NEVIRAPINE HEMIHYDRATE
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | Description: A white to almost white powder. Solubility: Practically insoluble in water, sparingly to slightly soluble in dichloromethane R, slightly soluble in methanol R. Category: Antiretroviral (Non-Nucleoside Reverse Transcriptase Inhibitor). Storage: Nevirapine should be kept in a well-closed container. Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form. Definition: Nevirapine contains not less than 98.0% and not more than 102.0% of nevirapine (C15H14N4O), calculated with reference to the anhydrous substance. | ||
|
9959243
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
2462459
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
DTXSID30176606
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
B7XF2TD73C
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
B7XF2TD73C
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
SUB34149
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY | |||
|
220988-26-1
Created by
admin on Fri Dec 15 21:18:13 GMT 2023 , Edited by admin on Fri Dec 15 21:18:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
ANHYDROUS->SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
Amount Not Specified
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
The test is not valid unless the resolution between nevirapine and nevirapine impurity B RS is not less than 5. In the chromatogram obtained with solution (3) the peak due to impurity (B) is eluted at a relative retention of about 0.7 with reference to nevirapine (retention time about 7.6 minutes).
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |